On January 29, 2013, Tevapharm India Pvt. Ltd. hosted the groundbreaking ceremony for its new multi-product, over-the-counter (OTC) manufacturing facility in Sanand, Ahmedabad district. The new Teva plant will be one of the largest state-of-the-art OTC medicine manufacturing sites in the world.
Speaking at the occasion, Mr. Eran Katz, Executive Vice President, Strategy and Operational Excellence for Teva Global Operations, said, “Teva is delighted to be building a state-of-the-art, multipurpose plant in India to support the growing demand for our non-prescription health care products across Asia. The Sanand facility represents a critical component of PGT Healthcare, Teva’s international partnership and joint venture with Procter & Gamble.”
Teva’s Sanand plant will be devoted to OTC manufacturing and will initially satisfy OTC production requirements for the domestic and Asia Pacific markets. This will include liquid, oral solid dosage and inhaler production including P&G’s current Vicks range of cough & cold medicines and throat drops in India, along with potentially other over-the-counter products for India and other markets.
The construction of the plant is expected to take approximately two years. The new plant will complement the existing network of Vicks contract manufacturers in India as the company plans to continue working with their current contract manufacturers even after this plant is operational. The modular design of the plant will enable Teva to further expand the plant as demand for consumer health care products continues to grow across the region and the globe.